Search
Foghorn Therapeutics Inc.
FHTXAdd to Watchlist
5.300USD
+0.290+5.79%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
311.17MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.79%
5 Days
+25.59%
1 Month
+41.71%
6 Months
+2.12%
Year to Date
-1.85%
1 Year
+3.31%
Key Figures
5.020Open
5.340High
401.70KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.68%Turnover Ratio
5.010Prev. Close
4.830Low
1.74MTurnover
LossP/E Static
-4.07P/B
0.00%Div Yield TTM
-31.33%ROA
6.95052wk High
1.30Volume Ratio
-86.62MNet Profit
58.71MShares
-1.1656EPS TTM
2.91Beta
-470.38%ROE
3.27052wk Low
10.18%Amplitude
100.00%Gross Margin
311.17MMarket Cap
7.91Reward/Risk
4.29%Risk Rate
TradingKey Stock Score of Foghorn Therapeutics Inc.
Currency: USD Updated: 2026-07-02Key Insights
Foghorn Therapeutics Inc.'s fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 82 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 11.44.In the medium term, the stock price is expected to remain stable.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Foghorn Therapeutics Inc.'s Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Foghorn Therapeutics Inc. Highlights
StrengthsRisks
Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.91M.
Undervalued
The company’s latest PE is -4.55, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.73M shares, decreasing 1.12% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 1.40K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.46.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
11.444
Target Price
+128.43%
Upside Space
Foghorn Therapeutics Inc. News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Foghorn Therapeutics Inc. Info
Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.
Ticker SymbolFHTX
CompanyFoghorn Therapeutics Inc.
CEOGottschalk (Adrian)
Websitehttps://foghorntx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Foghorn Therapeutics Inc. (FHTX)?
The current price of Foghorn Therapeutics Inc. (FHTX) is 5.30.
What is the symbol of Foghorn Therapeutics Inc.?
The ticker symbol of Foghorn Therapeutics Inc. is FHTX.
What is the 52-week high of Foghorn Therapeutics Inc.?
The 52-week high of Foghorn Therapeutics Inc. is 6.95.
What is the 52-week low of Foghorn Therapeutics Inc.?
The 52-week low of Foghorn Therapeutics Inc. is 3.27.
What is the market capitalization of Foghorn Therapeutics Inc.?
The market capitalization of Foghorn Therapeutics Inc. is 311.17M.
Is Foghorn Therapeutics Inc. (FHTX) currently rated as Buy, Hold, or Sell?
According to analysts, Foghorn Therapeutics Inc. (FHTX) has an overall rating of STRONG BUY, with a price target of 11.44.
What is the Earnings Per Share (EPS TTM) of Foghorn Therapeutics Inc. (FHTX)?
The Earnings Per Share (EPS TTM) of Foghorn Therapeutics Inc. (FHTX) is -1.18.